Bispecific antibodies (BsAbs) are emerging as an important novel class of
immunotherapeutic agents for the treatment of multiple myeloma (MM), and are set to be …

Multiple myeloma is an incurable cancer characterized by the uncontrolled growth of
malignant plasma cells nurtured within a permissive bone marrow microenvironment. While …

ALLO-715 is a first-in-class, allogeneic, anti-BCMA CAR T cell therapy engineered to
abrogate graft-versus-host disease and minimize CAR T rejection. We evaluated escalating …

Bispecific T cell engagers (TCEs) have shown promise in the treatment of various cancers,
but the immunological mechanism and molecular determinants of primary and acquired …

The use of bispecific antibodies (BsAbs) in the treatment of relapsed/refractory multiple
myeloma (MM) is showing early promising overall response rates in heavily pretreated …

Background Iberdomide is a novel cereblon E3 ligase modulator with enhanced
tumouricidal and immune-stimulatory effects compared with immunomodulatory drugs. In …

Bispecific antibodies, a novel immunotherapy with promising efficacy against multiple
myeloma, form immune synapses between T-cell surface marker CD3 and malignant cell …

Simple Summary Multiple myeloma (MM) is a frequent hematological malignancy
characterized by the uncontrolled growth of clonal plasma cells, primarily in the bone …

The treatment of multiple myeloma (MM) is evolving rapidly. In the past few years, chimeric
antigen receptor modified T cells and bispecific antibodies are bringing new treatment …

Bispecific antibodies are monoclonal antibodies targeting both a surface molecule on the
malignant plasma cells and CD3 on T cells, leading to tumor cell death by activated T cells …